TransMedics [TMDX] vs Abbott Laboratories [ABT] Detailed Stock Comparison

TransMedics Group Inc.

NASDAQ
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: TransMedics Group Inc. wins in 5 metrics, Abbott Laboratories wins in 14 metrics, with 0 ties. Abbott Laboratories appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric TransMedics Group Inc. Abbott Laboratories Better
P/E Ratio (TTM) 23.29 25.97 TransMedics Group Inc.
Price-to-Book Ratio 8.22 3.09 Abbott Laboratories
Debt-to-Equity Ratio 109.76 26.79 Abbott Laboratories
PEG Ratio 0.02 -1.41 TransMedics Group Inc.
EV/EBITDA 28.01 13.74 Abbott Laboratories
Profit Margin (TTM) 31.43% 13.90% TransMedics Group Inc.
Operating Margin (TTM) 13.23% 16.50% Abbott Laboratories
EBITDA Margin (TTM) 13.23% 16.50% Abbott Laboratories
Return on Equity 54.24% 12.36% TransMedics Group Inc.
Return on Assets (TTM) 7.25% 7.52% Abbott Laboratories
Free Cash Flow (TTM) $133.59M $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return -48.97% -34.98% Abbott Laboratories
Price-to-Sales Ratio (TTM) 6.47 3.57 Abbott Laboratories
Enterprise Value $3.77B $166.96B Abbott Laboratories
EV/Revenue Ratio 6.22 3.70 Abbott Laboratories
Gross Profit Margin (TTM) 58.11% N/A N/A
Revenue per Share (TTM) $18 $26 Abbott Laboratories
Earnings per Share (Diluted) $4.87 $3.57 TransMedics Group Inc.
Beta (Stock Volatility) 2.08 0.78 Abbott Laboratories
Short % of Float 36.27% 1.53% Abbott Laboratories

TransMedics Group Inc. vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

TMDX
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
TransMedics Group Inc.3.52%6.10%19.43%-39.47%-38.71%-38.48%
Abbott Laboratories0.56%-2.02%4.97%-19.35%-30.98%-28.60%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
TransMedics Group Inc.-48.97%-7.27%144.83%193.99%193.99%193.99%
Abbott Laboratories-34.98%-16.97%-20.08%135.84%255.56%329.52%

Performance & Financial Health Analysis: TransMedics Group Inc. vs Abbott Laboratories

MetricTMDXABT
Market Information
Market Cap i$3.91B$160.70B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i666,20713,495,583
90 Day Avg. Volume i896,75912,934,461
Last Close$75.48$88.67
52 Week Range$60.10 - $156.00$81.97 - $139.06
% from 52W High-51.62%-36.24%
All-Time High$177.37 (Aug 19, 2024)$142.60 (Dec 27, 2021)
% from All-Time High-57.44%-37.82%
Growth Metrics
Quarterly Revenue Growth0.32%0.08%
Quarterly Earnings Growth14.37%-0.19%
Financial Health
Profit Margin (TTM) i0.31%0.14%
Operating Margin (TTM) i0.13%0.17%
Return on Equity (TTM) i0.54%0.12%
Debt to Equity (MRQ) i109.7626.79
Cash & Liquidity
Book Value per Share (MRQ)$13.81$30.02
Cash per Share (MRQ)$14.24$5.14
Operating Cash Flow (TTM) i$192.84M$10.80B
Levered Free Cash Flow (TTM) i$94.00M$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A$2.40

Valuation & Enterprise Metrics Analysis: TransMedics Group Inc. vs Abbott Laboratories

MetricTMDX (Apr 24, 2026)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i23.2925.97
Forward P/E i30.8015.29
PEG Ratio i0.02-1.41
Price to Sales (TTM) i6.473.57
Price to Book (MRQ) i8.223.09
Market Capitalization
Market Capitalization i$3.91B$160.70B
Enterprise Value i$3.77B$166.96B
Enterprise Value Metrics
Enterprise to Revenue i6.223.70
Enterprise to EBITDA i28.0113.74
Risk & Other Metrics
Beta i2.080.78
Book Value per Share (MRQ) i$13.81$30.02

Financial Statements Comparison: TransMedics Group Inc. vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricTMDX (2025)ABT (2025)
Revenue/Sales i605.49M44.33B
Cost of Goods Sold i242.69M19.32B
COGS % of Revenue i40.1%43.6%
Gross Profit i362.81M25.01B
Gross Margin i59.9%56.4%
Research & Development i69.06M2.94B
Operating Income (EBIT) i108.58M8.05B
Operating Margin i17.9%18.2%
EBITDA i148.49M12.03B
EBITDA Margin i24.5%27.1%
Pre-Tax Income i107.52M8.47B
Pre-Tax Income % of Revenue i17.8%19.1%
Income Tax i-82.77M1.94B
Income Tax % of Revenue i-13.7%4.4%
Net Income (Profit) i190.29M6.52B
Profit Margin i31.4%14.7%

Balance Sheet & Liquidity Metrics

MetricTMDX (2025)ABT (2025)
Cash & Equivalents i488.37M8.52B
Total Current Assets i637.78M26.00B
Total Current Assets % of Revenue i105.3%58.6%
Total Current Liabilities i89.31M16.50B
Total Current Liabilities % of Revenue i14.7%37.2%
Long-Term Debt i505.97M10.83B
Long-Term Debt % of Revenue i83.6%24.4%
Total Shareholders Equity i473.10M52.77B
Retained Earnings i-277.95M49.78B
Retained Earnings % of Revenue i-45.9%112.3%
Property, Plant & Equipment i45.54M17.57B

Cash Flow Statement Comparison

MetricTMDX (2025)ABT (2025)
Operating Cash Flow i180.45M10.80B
Operating Cash Flow % of Revenue i29.8%24.4%
Capital Expenditures i-59.25M-2.17B
Free Cash Flow i133.59M7.40B
FCF Margin i22.1%16.7%
Debt Repayment iN/A-1.50B
Common Stock Repurchase iN/A-893.00M

Short Interest & Institutional Ownership Analysis

MetricTMDXABT
Shares Short i8.03M23.83M
Short Ratio i7.661.93
Short % of Float i36.27%1.53%
Shares Outstanding i34.27M1.74B
Float Shares i33.19M1.73B
% Held by Insiders i3.30%0.54%
% Held by Institutions i110.68%82.23%
% Held by Public i-13.98%17.23%

Dividend Analysis & Yield Comparison: TransMedics Group Inc. vs Abbott Laboratories

MetricTMDXABT
Last 12-Month Dividend iN/A$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$6.72
Ex-Dividend DateN/AJan 15, 2026